Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer.

被引：1
|
作者：
Zurcher, Jean-Philippe
Aedo, Veronica
Stravodimou, Athina
Sarivalasis, Apostolos
Zaman, Khalil
机构：
[1] Univ Hosp CHUV, Dept Oncol, Lausanne, Switzerland
[2] Univ Hosp CHUV, Breast Ctr, Lausanne, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13052
引用
收藏
页数：1
相关论文
共 50 条
  • [21] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [22] CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
    Roberto, Michela
    Astone, Antonio
    Botticelli, Andrea
    Carbognin, Luisa
    Cassano, Alessandra
    D'Auria, Giuliana
    Fabbri, Agnese
    Fabi, Alessandra
    Gamucci, Teresa
    Krasniqi, Eriseld
    Minelli, Mauro
    Orlandi, Armando
    Pantano, Francesco
    Paris, Ida
    Pizzuti, Laura
    Portarena, Ilaria
    Salesi, Nello
    Scagnoli, Simone
    Scavina, Paola
    Tonini, Giuseppe
    Vici, Patrizia
    Marchetti, Paolo
    CANCERS, 2021, 13 (02) : 1 - 20
  • [23] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Lu, Janice
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [24] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Janice Lu
    Journal of Hematology & Oncology, 8
  • [25] Does HER2 Affect CDK4/6 Pathway Activity in Breast Cancer?
    Cui, Xiaoyan
    Sinclair, William
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 92 - 94
  • [26] Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer
    Zhang, Cui
    Zhou, Fulin
    Zou, Jiali
    Fang, Yanman
    Liu, Yuncong
    Li, Libo
    Hou, Jing
    Wang, Guanghui
    Wang, Hua
    Lai, Xiaolian
    Xie, Lu
    Jiang, Jia
    Yang, Can
    Huang, Yisidan
    Chen, Yingji
    Zhang, Hanqun
    Li, Yong
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [27] Does HER2 Affect CDK4/6 Pathway Activity in Breast Cancer?
    Cui, Xiaoyan
    Sinclair, William
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 92 - 94
  • [28] Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) therapy in patients with advanced breast cancer: a single-centre experience
    Chawla, S.
    Parton, M.
    Johnston, S.
    Fearfield, L.
    Heelan, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 : 136 - 137
  • [29] The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
    Botticelli, Andrea
    Fabbri, Agnese
    Roberto, Michela
    Alesini, Daniele
    Cirillo, Alessio
    D'Auria, Giuliana
    Krasniqi, Eriseld
    Marrucci, Eleonora
    Muratore, Margherita
    Pantano, Francesco
    Pizzuti, Laura
    Portarena, Ilaria
    Rossi, Rosalina
    Scagnoli, Simone
    Marchetti, Paolo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
12345